EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Home‐Based Testing as an Approach to Estimate Influenza Vaccine Effectiveness in South Africa, 2021–2022—A Pilot Study

Jocelyn Moyes iD, Mvuyo Makhazi, Sibongile Walaza iD, Phiwokuhle Ntombela, Fahima Moosa, Anne von Gottberg, Nicole Wolter, Mignon du Plessis, Gillian Hunt, Cherie Cawood, Erica Dueger, Cheryl Cohen iD

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.70034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Jocelyn Moyes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johann…. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Surveillance programmes for influenza and other respiratory pathogens are important to generate vaccine effectiveness (VE) estimates and to inform vaccine composition. We aimed to explore the feasibility and acceptability of home‐based testing.

Methods

In three out of nine provinces in South Africa, we established a self‐referral system for individuals aged ≥ 18 years with respiratory symptoms of ≤ 10 days duration. Following consent, swab collection material was delivered to participants who also completed a questionnaire including self‐reported vaccination status. Swabs were tested by PCR for influenza, respiratory syncytial virus (RSV) and SARS‐CoV‐2. A test‐negative methodology was used to estimate influenza VE.

Results

Of 1456 samples collected between 19 November 2021 and 3 September 2022, 73 (5%) tested positive for influenza, 38 (3%) tested positive for RSV and 394 (27%) for SARS‐CoV‐2. We subtyped 55% (40/73) of the influenza positive specimens; 16/40 (40%) were influenza A(H1N1)pdm09; 10/40 (25%)A(H3N2)) and all 14/40(35%) influenza B were B/Victoria. Only 20% (279/1451) of participants reported influenza‐like illness case definition symptoms of fever and cough. Influenza vaccine coverage was 11% (157/1454). The overall influenza VE was 26% (95% confidence interval: −73%, 69%). Of the completed acceptability questionnaires, 123/127 (97%) participants would make use of the service again; 90% (1306) were recruited via the COVID‐19 testing centre (call in, social media, webpage), and 7% (99/1306) through CoughWatchSA .

Conclusions

Home‐based swabbing was feasible and acceptable. We were able to calculate an influenza VE, although a larger sample size and verification of vaccine status may improve the VE estimates in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza VaccinesCOVID-19HumansSouth AfricaPilot ProjectsAdultMaleFemaleMiddle AgedYoung AdultAdolescentSARS-CoV-2Vaccine EfficacyAgedVaccinationRespiratory Syncytial Virus InfectionsSurveys and Questionnaires

Stichwörter der Autor:innen

home‐based self swabbinginfluenzainfluenza vaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa.
  • School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • BARC Laboratories, Johannesburg, South Africa.
  • Epicentre Health Research, Hillcrest, South Africa.
  • Sanofi S.A., Paris, France.

ORCID-Profile: Jocelyn Moyes, Sibongile Walaza, Cheryl Cohen

Förderung

  • Sanofi

Zitieren

APA

Moyes, J., Makhazi, M., Walaza, S., Ntombela, P., Moosa, F., von Gottberg, A., Wolter, N., du Plessis, M., Hunt, G., Cawood, C., Dueger, E., & Cohen, C. (2024). Home‐Based Testing as an Approach to Estimate Influenza Vaccine Effectiveness in South Africa, 2021–2022—A Pilot Study. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70034

Vancouver

Moyes J, Makhazi M, Walaza S, Ntombela P, Moosa F, von Gottberg A, et al. Home‐Based Testing as an Approach to Estimate Influenza Vaccine Effectiveness in South Africa, 2021–2022—A Pilot Study. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.70034

BibTeX
@article{Moyes2024,
  author = {Moyes, Jocelyn and Makhazi, Mvuyo and Walaza, Sibongile and Ntombela, Phiwokuhle and Moosa, Fahima and von Gottberg, Anne and Wolter, Nicole and du Plessis, Mignon and Hunt, Gillian and Cawood, Cherie and Dueger, Erica and Cohen, Cheryl},
  title = {Home‐Based Testing as an Approach to Estimate Influenza Vaccine Effectiveness in South Africa, 2021–2022—A Pilot Study},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.70034}
}
Kostenlos starten →